F
FibroBiologics, Inc.
Period
FY 2025
Revenue
—
Net Income
$-18.65M
Total Assets
$9.62M
Equity
$6.16M
Shares Out
5.21M
Op. Cash Flow
$-16.39M
Business
FibroBiologics, Inc. is a clinical-stage biotechnology company developing fibroblast-based cell therapies for chronic diseases including wound healing, multiple sclerosis, degenerative disc disease, and psoriasis. The company's lead candidates are CYWC628 for diabetic foot ulcers, CYMS101 for multiple sclerosis, CybroCell™ for degenerative disc disease, and CYPS317 for psoriasis, with earlier-stage programs in cancer and longevity applications. FibroBiologics operates as a single company with integrated research, development, and manufacturing functions, leveraging a fibroblast technology platform and partnering with CDMOs for clinical and commercial manufacturing.
Summary from 10-K filed 2026-02-24
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Research and development | 7 | 5 | 2 | 1 | |
| General, administrative and other | 9 | 9 | 7 | 3 | |
| Total operating expenses | 17 | 14 | 9 | 4 | |
| Loss from operations | −17 | −14 | −9 | −4 | |
| Change in fair value of warrant liability | 0 | 5 | −7 | — | |
| Change in fair value of forward contract liability | 0 | −417,000 | — | — | |
| Change in fair value of SEPA put option liability | 352,000 | −460,000 | — | — | |
| Change in fair value of convertible debt | −2 | 232,000 | — | — | |
| Commitment fee expenses | 0 | −2 | — | — | |
| Placement agent and tail fee expenses | 0 | −1 | — | — | |
| Other income/(expense) | −619,000 | 32,000 | −213,000 | — | |
| Gain on termination of warrant and commitment fee liabilities | 0 | 1 | — | — | |
| Interest income | 247,000 | 251,000 | — | — | |
| Interest expense | −204,000 | −20,000 | −147,000 | — | |
| Total other income/(expense) | −2 | 3 | −213,000 | — | |
| Net loss | −19 | −11 | −16 | −5 | |
| Net loss per share, basic | −0.42 | −0.34 | −0.68 | −0.18 | |
| Net loss per share, diluted | −0.42 | −0.34 | −0.68 | −0.18 | |
| Weighted-average shares outstanding, basic | 45 | 33 | 28 | 28 | |
| Weighted-average shares outstanding, diluted | 45 | 33 | 28 | 28 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 5 | 14 | 9 | 2 | — | |
| Prepaid expenses | 1 | 225,000 | 36,000 | 29,000 | — | |
| Other current assets | 0 | 18,000 | 16,000 | 30,000 | — | |
| Total current assets | 6 | 14 | 9 | 3 | — | |
| Property and equipment, net | 842,000 | 824,000 | 797,000 | — | — | |
| Operating lease right-of-use asset, net | 2 | 1 | 2 | 2 | — | |
| Other assets | 48,000 | 0 | — | — | — | |
| Total assets | 10 | 16 | 12 | 5 | — | |
| Accounts payable and accrued expenses | 945,000 | 3 | 1 | 758,000 | — | |
| Operating lease liability, short-term | 706,000 | 401,000 | 362,000 | 326,000 | — | |
| SEPA put option liability | 108,000 | 460,000 | — | — | — | |
| Short-term convertible debt | 0 | 9 | — | — | — | |
| Total current liabilities | 2 | 13 | 9 | 7 | — | |
| Operating lease liability, long-term | 2 | 984,000 | 1 | 2 | — | |
| Total liabilities | 3 | 14 | 11 | 9 | — | |
| Preferred Stock, value | 0 | 0 | — | — | — | |
| Voting Common Stock, $0.00001 par value; 300,000,000 shares and 100,000,000 shares authorized as of December 31, 2025 and 2024, respectively; 66,519,722 shares and 35,085,718 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 1,000 | 0 | — | — | — | |
| Additional paid-in capital | 60 | 38 | 26 | 2 | — | |
| Accumulated deficit | −54 | −36 | −24 | −8 | — | |
| Total stockholders equity | 6 | 3 | 1 | −4 | −1 | |
| Total liabilities and stockholders equity | 10 | 16 | 12 | 5 | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Change in fair value of convertible debt | 2 | −232,000 | — | — | |
| Commitment fee expense | 0 | 2 | — | — | |
| Non-cash discount on convertible debt | 625,000 | 0 | 81,000 | 389,000 | |
| Stock-based compensation expense | 3 | 2 | 2 | 265,000 | |
| Amortization of operating lease right-of-use asset | 588,000 | 416,000 | 390,000 | 94,000 | |
| Depreciation expense | 200,000 | 200,000 | 47,000 | — | |
| Prepaid expenses | −1 | −189,000 | −7,000 | 8,000 | |
| Accounts payable and accrued expenses | −2 | 1 | 671,000 | 525,000 | |
| Other current assets | 18,000 | −2,000 | 14,000 | −6,000 | |
| Other assets | −48,000 | 0 | — | — | |
| Payable to Parent | 0 | −141,000 | 141,000 | — | |
| Operating lease liability | −550,000 | −362,000 | −326,000 | −220,000 | |
| Net cash used in operating activities | −16 | −12 | −6 | −4 | |
| Purchases of property and equipment | −262,000 | −184,000 | −495,000 | — | |
| Net cash used in investing activities | −262,000 | −184,000 | −495,000 | — | |
| Proceeds from short-term convertible debt | 4 | 9 | — | 4 | |
| Proceeds from short-term borrowing | 0 | 574,000 | — | — | |
| Repayments of short-term borrowing | 0 | −574,000 | — | — | |
| Repayments of short-term convertible debt | −3 | 0 | — | — | |
| Proceeds from issuance of common stock, net of direct costs | 7 | 8 | — | — | |
| Net cash provided by financing activities | 8 | 17 | 14 | 6 | |
| Net decrease in cash and cash equivalents | −9 | 5 | 7 | 2 | |
| Cash paid for income taxes | 0 | 0 | — | — | |
| Cash paid for interest | 204,000 | 20,000 | 2,000 | — | |
| Settlement of forward contract liability for sale of shares to GEM pursuant to Draw Down and Closing Notices | 0 | 417,000 | — | — | |
| Issuance of Voting Common Stock to terminate Share Subscription Agreement | 0 | 3 | — | — | |
| Additions to accounts payable and accrued expenses for purchases of property and equipment | 0 | 17,000 | 349,000 | — | |
| Right of use asset obtained in exchange for operating lease liability | 2 | 0 | — | — | |
| Issuance of Voting Common Stock for commitment fee payable | 250,000 | 0 | — | — | |
| Conversion of Short-term convertible note payable into shares of common stock | 13 | 0 | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is FibroBiologics, Inc.'s CIK number?
FibroBiologics, Inc.'s SEC CIK number is 0001958777 (1958777). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find FibroBiologics, Inc.'s SEC filings?
All of FibroBiologics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.